Викторина, связанная с руководством · Средний Уровень

Тест по искусственному интеллекту в заболеваниях печени и гепатологии

Тестирует оценку патологии печени, ультразвуковые исследования, модели риска трансплантации, область квалификации FDA и профессиональную оценку.

Связанные направляющие путиИИ при заболеваниях печени и гепатологии
Вопрос 1 из 8

For what setting did FDA qualify AIM-NASH as a drug-development tool?

Предварительный просмотр каждого вопроса8 вопросы

Ответы и пояснения появляются по мере прохождения теста.

  1. For what setting did FDA qualify AIM-NASH as a drug-development tool?
    • Diagnosing all liver diseases from a blood test
    • Setting transplant priority in every country
    • Scoring liver-biopsy features in MASH clinical trials
    • Replacing liver biopsy with ultrasound
  2. Who makes the final interpretation of an AIM-NASH biopsy score?
    • The AI tool alone
    • The pathologist after reviewing the whole slide and AI output
    • The trial sponsor
    • A transplant coordinator
  3. Why should ultrasound and biopsy AI results be treated as different tasks?
    • Every imaging method measures the same tissue directly
    • A biopsy model automatically validates ultrasound
    • Ultrasound tools never use AI
    • They use different inputs and reference standards
  4. What did the GEMA-AI study estimate?
    • A waitlist outcome estimate for transplant candidates using clinical variables
    • A histology grade for steatosis in biopsy images
    • A radiology score for liver ultrasound texture
    • A classification of cancer-signal origin in blood
  5. Does a research model automatically become a transplant allocation rule?
    • Yes, once it has an external test set
    • Yes, when it uses the same lab variables
    • No; allocation requires policy and multidisciplinary review
    • No, because prediction models cannot use lab results
  6. Which liver-biopsy features does AIM-NASH score?
    • Kidney filtration, blood pressure and sodium only
    • Steatosis, inflammation and fibrosis
    • Thyroid shape, margin and echogenicity
    • Tumor stage and medication response
  7. What should a liver imaging team check before using an AI fibrosis score?
    • That the model was trained on any organ image
    • Only whether the report is short
    • Whether a transplant list is available
    • That the model was validated for the relevant imaging task and patient group
  8. What remains central in transplant allocation decisions?
    • Policy, equity, organ availability and transplant-team review
    • The highest model score alone
    • An ultrasound image without other information
    • A model vendor’s ranking